Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease

Zhu, Yongyun; Yang, Baiyuan; Wang, Fang; Liu, Bin; Li, Kelu; Yin, Kangfu; Yin, Wei; Zhou, Chen; Tian, Sijia; Ren, Hui; Pang, Ailan; Yang, Xinglong

doi:10.1016/j.jneuroim.2021.577662

Cited by 16 publications

(13 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the research on this aspect is still controversial. One study about the association between plasma NFL and cognitive mentioned that PD patients with RBD had higher NFL levels than those without RBD (Zhu et al, 2021), consistent with our findings. On the contrary, another study based on 77 PD patients proved that there was no difference in plasma NFL level according to the presence or absence of RBD in PD patients (Park et al, 2021).…”

Section: Discussionsupporting

confidence: 92%

The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease

Teng

Mao

et al. 2023

Journal of Neurochemistry

View full text Add to dashboard Cite

Studies have shown that rapid eye movement (REM) sleep behavior disorder (RBD) is a subtype of Parkinson's disease (PD) characterized by severe cognitive impairment and rapid disease progression. However, reliable biological markers are lacking presently.Neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP) have been widely studied as biomarkers of cognition impairment. This study aimed to find biomarkers for the RBD subtype of PD by investigating the possible relationship between serum NFL, GFAP levels, and the RBD subtype. A total of 109 PD patients and 37 healthy controls (HCs) were included, and their clinical characteristics were evaluated. PD patients were divided into two groups based on whether they had probable RBD or not. Serum NFL and GFAP levels were measured using the ultrasensitive single molecule array (Simoa) platform. The obtained data were statistically analyzed using SPSS 25.0 (IBM, Chicago, IL, USA). NFL and GFAP in the PD-RBD group were elevated compared with the PD-nRBD and control groups. Moreover, serum NFL and GFAP levels positively correlated with RBD. The combination of NFL and GFAP showed good performance in identifying PD-RBD patients from PD-nRBD. After considering potential confounding factors such as age, and disease duration, serum NFL and GFAP emerged as independent risk factors for RBD. Serum NFL and GFAP were related to RBD in PD patients. Concludingly, serum NFL and GFAP might serve as promising biomarkers for the RBD subtype of PD.

show abstract

Section: Discussionsupporting

confidence: 92%

The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease

Teng

Mao

et al. 2023

Journal of Neurochemistry

View full text Add to dashboard Cite

show abstract

“…In chronic neurodegenerative disease and multiple sclerosis, high NF-L levels are associated with cognitive impairment [ 41 , 42 , 43 , 44 ]. Rats with severe lateral FPI-induced TBI show hippocampus-dependent memory deficits already on D2 after TBI and remain impaired for months [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Plasma Neurofilament Light Chain (NF-L) Is a Prognostic Biomarker for Cortical Damage Evolution but Not for Cognitive Impairment or Epileptogenesis Following Experimental TBI

Heiskanen

Jääskeläinen

Manninen

et al. 2022

IJMS

View full text Add to dashboard Cite

Plasma neurofilament light chain (NF-L) levels were assessed as a diagnostic biomarker for traumatic brain injury (TBI) and as a prognostic biomarker for somatomotor recovery, cognitive decline, and epileptogenesis. Rats with severe TBI induced by lateral fluid-percussion injury (n = 26, 13 with and 13 without epilepsy) or sham-operation (n = 8) were studied. During a 6-month follow-up, rats underwent magnetic resonance imaging (MRI) (day (D) 2, D7, and D21), composite neuroscore (D2, D6, and D14), Morris-water maze (D35–D39), and a 1-month-long video-electroencephalogram to detect unprovoked seizures during the 6th month. Plasma NF-L levels were assessed using a single-molecule assay at baseline (i.e., naïve animals) and on D2, D9, and D178 after TBI or a sham operation. Plasma NF-L levels were 483-fold higher on D2 (5072.0 ± 2007.0 pg/mL), 89-fold higher on D9 (930.3 ± 306.4 pg/mL), and 3-fold higher on D176 32.2 ± 8.9 pg/mL after TBI compared with baseline (10.5 ± 2.6 pg/mL; all p < 0.001). Plasma NF-L levels distinguished TBI rats from naïve animals at all time-points examined (area under the curve [AUC] 1.0, p < 0.001), and from sham-operated controls on D2 (AUC 1.0, p < 0.001). Plasma NF-L increases on D2 were associated with somatomotor impairment severity (ρ = −0.480, p < 0.05) and the cortical lesion extent in MRI (ρ = 0.401, p < 0.05). Plasma NF-L increases on D2 or D9 were associated with the cortical lesion extent in histologic sections at 6 months post-injury (ρ = 0.437 for D2; ρ = 0.393 for D9, p < 0.05). Plasma NF-L levels, however, did not predict somatomotor recovery, cognitive decline, or epileptogenesis (p > 0.05). Plasma NF-L levels represent a promising noninvasive translational diagnostic biomarker for acute TBI and a prognostic biomarker for post-injury somatomotor impairment and long-term structural brain damage.

show abstract

“…Physiologically, cognitive processing speed is dependent on the integrity of long caliber brain fibers, in which NfL is abundantly expressed [18] . Age-related atrophy or reduction in brain metabolism may lead to axonal degeneration and an increase in NfL levels [19] . Recently, [20] 2 studies have discovered that NfL is a sensitive marker for micro-structural brain alterations (e.g., of white matter fiber tracts) that are related for cognitive functioning [21] .…”

Section: Discussionmentioning

confidence: 99%

“…[18] Age-related atrophy or reduction in brain metabolism may lead to axonal degeneration and an increase in NfL levels. [19] Recently, [20] 2 studies have discovered that NfL is a sensitive marker for micro-structural brain alterations (e.g., of white matter fiber tracts) that are related for cognitive functioning. [21] Further studies of pathogenesis of MCI are needed.…”

Section: Discussionmentioning

confidence: 99%

Neurofilament light chain in cerebrospinal fluid or blood as a biomarker for mild cognitive impairment

et al. 2022

View full text Add to dashboard Cite

Background: To allow early diagnosis and monitoring of disease progression, there is a need for biomarkers in mild cognitive impairment (MCI). Neurofilament light chain (NfL) is emerging protein biomarkers in neurodegenerative diseases and is of possible use in MCI. We aimed to assess the utility of NfL in blood and cerebrospinal fluid (CSF) as a biomarker in patients with MCI.Methods: A systematic search with comparison of NfL level between individuals with MCI and healthy controls were retrieved from PubMed, Embase, and Web of Science. The standard mean difference and 95% confidence interval were calculated using the random-effect model to analyze the differentiation of NfL between patients and controls.Results: A total of 7 studies were included. NfL was higher in 676 MCI than 504 healthy controls. Subgroup analysis according to sample type indicated that differentiation of NfL in CSF between patients with MCI and controls showed significant results but in blood. Moreover, the NfL increasing still existed when the NfL expression level was detected by enzyme-linked immunosorbent assay but single molecule array assay. However, no difference of NfL in MCI between Caucasian and Asian was found.Conclusions: NfL expression level in CSF was increased in MCI individuals, which indicated that NfL in CSF could be a potential biomarker of MCI.

show abstract

Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease

Cited by 16 publications

References 51 publications

The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease

The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease

Plasma Neurofilament Light Chain (NF-L) Is a Prognostic Biomarker for Cortical Damage Evolution but Not for Cognitive Impairment or Epileptogenesis Following Experimental TBI

Neurofilament light chain in cerebrospinal fluid or blood as a biomarker for mild cognitive impairment

Contact Info

Product

Resources

About